Patents Examined by Amy Juedes
  • Patent number: 9907819
    Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 6, 2018
    Inventor: Kenichiro Hasumi
  • Patent number: 9879082
    Abstract: A novel IgG4 isotype anti-KIR antibody, novel formulations of this and other IgG4 anti-KIR antibodies, and methods of using such formulations are provided. Also described are compositions, formulations, dosages, and administration regimens suitable for NK cell activation and therapeutic applications of anti-KIR antibodies, as well as kits comprising one or more anti-KIR antibodies with instructions for use in treating cancer.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: January 30, 2018
    Assignee: NOVO NORDISK A/S
    Inventors: Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Rozana Sten, Lene Hjorth Alifrangis, Rune Viig Overgaard
  • Patent number: 9862968
    Abstract: The invention relates to dendritic cells, the NF?B signaling pathway of which has been manipulated by RNA transfection, to the manufacture thereof and to use thereof.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: January 9, 2018
    Assignee: Friedrich-Alexander-Universität Erlangen-Nürnberg
    Inventors: Katrin Birkholz, Jan Dörrie, Niels Schaft, Gerold Schuler, Reinhard Voll, Isabell Pfeiffer
  • Patent number: 9822163
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: November 21, 2017
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn
  • Patent number: 9822161
    Abstract: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: November 21, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Nicole Suciu-Foca, George Vlad, Raffaello Cortesini
  • Patent number: 9801911
    Abstract: The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 31, 2017
    Assignee: The Regents of the University of California
    Inventors: Qizhi Tang, Jeffrey A. Bluestone
  • Patent number: 9758592
    Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: September 12, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Dipali Deshpande, Gang Chen, Darya Burakov, James Fandl, Thomas Aldrich, Vishal Kamat
  • Patent number: 9751940
    Abstract: The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: September 5, 2017
    Assignee: RSR LIMITED
    Inventors: Bernard Rees Smith, Jadwiga Furmaniak, Jane Fina Sanders
  • Patent number: 9744233
    Abstract: Novel methods for treating patients with autoimmune diseases are disclosed. The methods of the invention include first depleting circulating lymphocytes in the mammal, e.g., by administering anti-thymocyte antibody, and then, during the course of repopulation, administering to the mammal a therapeutically effective amount of latent TGF-? and/or another agent that promotes expansion of regulatory T cells. In certain aspects, the disclosed process results in improved kidney function and survival rates.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: August 29, 2017
    Inventors: Johanne Kaplan, John McPherson
  • Patent number: 9737593
    Abstract: Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and/or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 22, 2017
    Assignee: Yale University
    Inventors: Tarek M. Fahmy, Lisa D. Pfefferle, Gary L. Haller
  • Patent number: 9732140
    Abstract: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically suited for said purpose, antibodies against said specific soluble CD83 proteins and assay methods and kits comprising said antibodies.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: August 15, 2017
    Inventors: Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
  • Patent number: 9717777
    Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: August 1, 2017
    Inventors: Nathan Karin, Yiftah Barsheshet, Gizi Wildbaum
  • Patent number: 9714289
    Abstract: The present invention is directed to anti-PVRIG antibodies and methods of using same.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: July 25, 2017
    Assignee: Compugen Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Leonard Presta, Richard Theolis
  • Patent number: 9708403
    Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: July 18, 2017
    Inventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Petrus Johannes Louis Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
  • Patent number: 9695397
    Abstract: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: July 4, 2017
    Assignee: Immunovative Therapies Ltd.
    Inventor: Michael Har-Noy
  • Patent number: 9694059
    Abstract: The present invention relates to an ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases. At the same time, it is related to a cellular composition that contributes to stimulate the activated antigen-presenting cells to induce a specific immune response against tumors in patients with cancer or other pathologies involving immune responses.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: July 4, 2017
    Assignee: Universidad de Chile
    Inventors: Flavio Andres Salazar Onfray, Mercedes Natalia Lopez Nitsche, Cristian Javier Pereda Ramos, Raquel Elvira Aguilera Insunza, Alejandro Felipe Escobar Alvarez
  • Patent number: 9676832
    Abstract: The present invention provides a dendritic cell modulatory protein which modulates, and preferably inhibits, the differentiation and/or maturation of mammalian dendritic cells. The invention also provides proteins comprising conserved motifs found in such proteins as well as pharmaceutical compositions comprising the dendritic cell modulatory protein and homologs and active fragments thereof, antibodies thereto and methods of treatment which utilize such proteins, homologs, fragments and antibodies.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: June 13, 2017
    Inventors: Jonathan M. Austyn, Guido Paesen, Stephen Preston, Patricia Nuttal
  • Patent number: 9670283
    Abstract: The present invention relates to antibodies targeted to BDCA2 that deplete plasmacytoid dendritic cells (pDC) and methods of using the antibodies to treat disorders associated with pDC.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: June 6, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Lishan Su
  • Patent number: 9657102
    Abstract: The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: May 23, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Smith, Nicholas J. Papadopoulos
  • Patent number: 9644013
    Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: May 9, 2017
    Inventors: Hiromi Kumon, Masami Watanabe, Junichiro Futami, Yasuyuki Fujii, Hideo Ueki, Kazuhiko Ochiai